The CASH study is a randomized, double-blind, placebo-controlled trial evaluating whether adding cilostazol to standard nimodipine therapy improves neurological outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). The primary objective is to assess functional outcome at 6 months using the modified Rankin Scale. A total of 630 patients will be enrolled within 96 hours of aSAH onset and treated for 14 days. The study is conducted across 9 centers in France, funded by a PHRC, and overseen by an independent monitoring board.
Adult patients admitted to an ICU with SAH related to a ruptured cerebral aneurysm occurring within the last 96 hours.
Aneurysm successfully secured by surgical clipping or endovascular coiling
Consent of the patient or, if not possible, from a proxy (emergency clause).
Registration in a national health care system
- Precritical modified Rankin Scale (mRS) > 2
Nonaneurysmal SAH
Delayed >96h admission after first symptoms of SAH
Coma defined by GCS of 3-5 with untreatable aneurysm will be excluded"